Compare Figs Inc (FIGS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs BIO-TECHNE Corp — how do they compare? Figs Inc trades at $14.96 (market cap $2.34B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 4.9× Figs Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Figs Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 33 Days and BIO-TECHNE Corp for 63 Days on average.
| FIGS | TECH | |
|---|---|---|
Market Cap | $2.34B | $11.37B |
Volume | 6,865,366 | 3,153,511 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $72.61 |
52-Week Low | $6.90 | $43.31 |
Typical Hold Time | 33 Days | 63 Days |
Enterprise Value | $2.10B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS trades at $14.06, down 0.28% today, with a bullish technical signal from moving averages. The company shows strong revenue growth from $556M in 2024 to $631M in 2025, with net income surging to $34M. Recent quarters have consistently beaten EPS expectations, and international sales grew 67% in Q2 2026. Analyst consensus is bullish with a $18.00 price target suggesting 28% upside potential from current levels.
The outlook remains positive with accelerating growth and margin expansion, though the stock's rich valuation (P/E 42.6) presents risk if execution falters. Key catalysts include continued international expansion and sustained demand from healthcare professionals, while risks include premium valuation pressure and competitive threats in medical apparel.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
